Abstract:To reduce time and cost, virtual ligand screening (VLS) often precedes experimental ligand screening in modern drug discovery. Traditionally, high-resolution structure-based docking approaches rely on experimental structures, while ligand-based approaches need known binders to the target protein and only explore their nearby chemical space. In contrast, our structure-based FINDSITEcomb2.0 approach takes advantage of predicted, low-resolution structures and information from ligands that bind distantly related proteins whose binding sites are similar to the target protein. Using a boosted tree regression machine learning framework, we significantly improved FINDSITEcomb2.0 by integrating ligand fragment scores as encoded by molecular fingerprints with the global ligand similarity scores of FINDSITEcomb2.0. The new approach, FRAGSITE, exploits our observation that ligand fragments, e.g., rings, tend to interact with stereochemically conserved protein subpockets that also occur in evolutionarily unrelated proteins. FRAGSITE was benchmarked on the 102 protein DUD-E set, where any template protein whose sequence identify >30% to the target was excluded. Within the top 100 ranked molecules, FRAGSITE improves VLS precision and recall by 14.3 and 18.5%, respectively, relative to FINDSITEcomb2.0. Moreover, the mean top 1% enrichment factor increases from 25.2 to 30.2. On average, both outperform state-of-the-art deep learning-based methods such as AtomNet. On the more challenging unbiased set LIT-PCBA, FRAGSITE also shows better performance than ligand similarity-based and docking approaches such as two-dimensional ECFP4 and Surflex-Dock v.3066. On a subset of 23 targets from DEKOIS 2.0, FRAGSITE shows much better performance than the boosted tree regression-based, vScreenML scoring function. Experimental testing of FRAGSITE's predictions shows that it has more hits and covers a more diverse region of chemical space than FINDSITEcomb2.0. For the two proteins that were experimentally tested, DHFR, a well-studied protein that catalyzes the conversion of dihydrofolate to tetrahydrofolate, and the kinase ACVR1, FRAGSITE identified new small-molecule nanomolar binders. Interestingly, one new binder of DHFR is a kinase inhibitor predicted to bind in a new subpocket. For ACVR1, FRAGSITE identified new molecules that have diverse scaffolds and estimated nanomolar to micromolar affinities. Thus, FRAGSITE shows significant improvement over prior state-of-the-art ligand virtual screening approaches. A web server is freely available for academic users at <a class="extLink" href="http://http:/sites.gatech.edu/cssb/FRAGSITE">http:/sites.gatech.edu/cssb/FRAGSITE</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01160</a>.Additional information for experimental methods and (Tables S1 and S2) top 40 most frequent fragments in DrugBank drugs and performance of methods for individual DUD-E targets using the modeled target structure (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01160/suppl_file/ci0c01160_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Crystallographic fragment screening of CDK2-cyclin A: FragLites map sites of protein-protein interaction

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

High-throughput discovery and deep characterization of cyclin-CDK docking motifs

KinaFrag Explores the Kinase-Ligand Fragment Interaction Space for Selective Kinase Inhibitor Discovery

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes

A comparative study of fragment screening methods on the p38α kinase: new methods, new insights

Mapping protein conformational landscapes from crystallographic drug fragment screens

Global profiling of protein complex dynamics with an experimental library of protein interaction markers

Classification of likely functional class for ligand binding sites identified from fragment screening

Protein X-ray Crystallography and Drug Discovery

In-Crystal Affinity Ranking Of Fragment Hit Compounds Reveals A Relationship With Their Inhibitory Activities

Screening, Growing, and Validation by Catalog: Using Synthetic Intermediates from Natural Product Libraries to Discover Fragments for an Aspartic Protease Through Crystallography

An expanded view of ligandability in the allosteric enzyme PTP1B from computational reanalysis of large-scale crystallographic data

Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.

Ligand and Target Discovery by Fragment-Based Screening in Human Cells

Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors